A Study of IMC-002 in Patients With Advanced Cancer Failed to Standard Therapy
ImmuneOncia Therapeutics Inc.
ImmuneOncia Therapeutics Inc.
University of Rochester
Bristol-Myers Squibb
Weill Medical College of Cornell University
Shanghai Allink Biotherapeutics Co., Ltd.
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Cancer Commons
Weill Medical College of Cornell University
Singapore General Hospital
University of Colorado, Denver
Canadian Cancer Trials Group
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bristol-Myers Squibb
Duke University
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Suzhou Transcenta Therapeutics Co., Ltd.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
NYU Langone Health
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bristol-Myers Squibb
Bristol-Myers Squibb
Agenus Inc.
Bristol-Myers Squibb
Prescient Therapeutics, Ltd.
Anwita Biosciences
ElmediX
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
University Health Network, Toronto
HC Biopharma Inc.
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
National Taiwan University Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bristol-Myers Squibb